Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) was downgraded by analysts at Jefferson Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Stock Ratings Network reports.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, January 30th. The company reported $0.87 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million.

Other equities research analysts have also recently issued reports about the stock. Analysts at Deutsche Bank raised their price target on shares of Alexion Pharmaceuticals from $125.00 to $205.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Friday, February 7th. They now have a $189.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, February 4th. They now have a $170.00 price target on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $159.61.

In other Alexion Pharmaceuticals news, EVP Stephen Squinto sold 7,055 shares of Alexion Pharmaceuticals stock on the open market in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $158.04, for a total value of $1,114,972.20. Following the completion of the sale, the executive vice president now directly owns 101,308 shares in the company, valued at approximately $16,010,716. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.